Acumen (NASDAQ: ABOS) insider to sell 36,911 shares under Rule 144

Rhea-AI Filing Summary

Acumen Pharmaceuticals, Inc. insider Derek Meisner filed a notice of proposed sale under Rule 144 covering 36,911 shares of common stock through broker Merrill Lynch on or about 01/08/2026, with an aggregate market value of $67,244.23, to be sold on NASDAQ.

The shares to be sold were acquired through vesting of restricted stock unit awards granted under the issuer’s equity compensation plan on several dates in 2025 and 2026. The notice also lists prior sales during the past three months, including 4,000 shares on 01/05/2026, 10,898 shares on 01/06/2026, and 11,770 shares on 01/07/2026. Common shares outstanding were 60,573,425 as of the figure shown in the filing, which serves as a baseline for the company’s equity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	36911	67244.23	60573425	01/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/02/2025	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			9025	01/02/2025	Granted as part of issuer equity compensation plan
Common stock	01/06/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			6819	01/06/2026	Granted as part of issuer equity compensation plan
Common stock	01/02/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			15521	01/02/2026	Granted as part of issuer equity compensation plan
Common stock	01/16/2025	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			5515	01/16/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7838.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	10898	21437.56
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	11770	23414.63

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Acumen Pharmaceuticals (ABOS) disclose?

The filing shows that Derek Meisner, an insider of Acumen Pharmaceuticals, Inc., has filed a notice of proposed sale under Rule 144 to sell up to 36,911 shares of common stock through Merrill Lynch on or about 01/08/2026 on the NASDAQ exchange.

How many Acumen Pharmaceuticals shares are planned to be sold and at what value?

The notice covers a proposed sale of 36,911 shares of Acumen Pharmaceuticals common stock with an indicated aggregate market value of $67,244.23, to be executed via Merrill Lynch on NASDAQ.

How did the insider acquire the Acumen Pharmaceuticals (ABOS) shares being sold?

The shares listed for sale were acquired through vesting of restricted stock unit awards granted as part of Acumen Pharmaceuticals’ equity compensation plan, with vesting dates including 01/02/2025, 01/16/2025, 01/02/2026, and 01/06/2026.

What recent Acumen Pharmaceuticals insider sales are disclosed in the past 3 months?

The filing lists sales by Derek Meisner over the past three months, including 4,000 shares of common stock on 01/05/2026 for $7,838.00, 10,898 shares on 01/06/2026 for $21,437.56, and 11,770 shares on 01/07/2026 for $23,414.63.

How many Acumen Pharmaceuticals shares are outstanding in this Form 144?

The securities information section reports that 60,573,425 shares of Acumen Pharmaceuticals common stock were outstanding, providing a reference point for the company’s total equity base relative to the insider’s planned sale.

Which broker will handle the planned Acumen Pharmaceuticals (ABOS) Rule 144 sale?

The Form 144 lists Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281, as the broker for the proposed sale of 36,911 Acumen Pharmaceuticals common shares on NASDAQ.